Bolt Biotherapeutics, Inc. Reports Q3 Loss, Tops Revenue Estimates
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
About 56% of ImmunoCellular Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading ImmunoCellular Therapeutics pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with ImmunoCellular Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use ImmunoCellular Therapeutics stock news signals to limit their universe of possible portfolio assets.
ImmunoCellular |
Bolt Biotherapeutics delivered earnings and revenue surprises of -11.11 percent and 12.30, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock
Read at zacks.com
 |
ImmunoCellular Therapeutics Fundamental Analysis
We analyze ImmunoCellular Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoCellular Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoCellular Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
ImmunoCellular Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
ImmunoCellular Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmunoCellular Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of ImmunoCellular Therapeutics could also be used in its relative valuation, which is a method of valuing ImmunoCellular Therapeutics by comparing valuation metrics with similar companies.
Peers
ImmunoCellular Therapeutics Related Equities
| PHGUF | Pharming Group | 1.33 | ||||
| LUMO | Lumos Pharma | 0.23 | ||||
| CPRX | Catalyst Pharmaceuticals | 0.19 | ||||
| NWBO | Northwest Biotherapeutics | 3.33 | ||||
| BOLT | Bolt Biotherapeutics | 5.36 | ||||
| CLRB | Cellectar Biosciences | 16.13 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |